Filing Flows › Nautilus Biotechnology (NAUT) › Q3 2026 › vs Q2 2026
Nautilus Biotechnology (NAUT) Q3 2026 vs Q2 2026 (quarter over quarter)
Nautilus Biotechnology's revenue rose $44K (+23%) from $190K in Q2 2026 to $234K in Q3 2026.
Nautilus Biotechnology, Q3 2026: revenue $234K, net loss $15.6M, operating cash flow −$13.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $234K | $190K | $44K | +23% |
| Net loss | $15.6M | $14.5M | $1.2M | +8% |
| Costs & expenses | $15.9M | $14.7M | $1.2M | +8% |
| Operating costs | $15.9M | $14.7M | $1.2M | +8% |
| Operating cash sources | $15.6M | $14.5M | $1.2M | +8% |
| Depreciation | $200K | $300K | −$100K | -33% |
| Share-based compensation | $1.3M | $1.2M | $134K | +12% |
| Working capital & other | $863K | −$715K | $1.6M | — |
| Cash used in operations | $13.3M | $13.7M | −$445K | -3% |
| Net loss absorbed | $15.6M | $14.5M | $1.2M | +8% |
Questions
How much did Nautilus Biotechnology's revenue grow quarter over quarter in Q3 2026?
Nautilus Biotechnology's revenue rose $44K (+23%) from $190K in Q2 2026 to $234K in Q3 2026.